Patent Power: Roche Concedes Case Over Amgen's EPO
This article was originally published in The Pink Sheet Daily
Executive Summary
Roche will not launch its anemia drug Mircera in the U.S. until Amgen's latest patent expires in 2015 unless it obtains a license.